Hepatitis A vaccines

@article{Nothdurft2008HepatitisAV,
  title={Hepatitis A vaccines},
  author={Hans Dieter Nothdurft},
  journal={Expert Review of Vaccines},
  year={2008},
  volume={7},
  pages={535 - 545}
}
  • H. Nothdurft
  • Published 1 July 2008
  • Medicine, Biology
  • Expert Review of Vaccines
The global disease burden associated with hepatitis A virus (HAV) is expected to increase in the coming years due to a shift in the epidemiological pattern of the disease. A decrease in the prevalence of natural immunity is leading to an increased number of adolescents and adults susceptible to a disease that is associated with greater morbidity, mortality and treatment costs in older-age groups. Current HAV vaccines have been shown to be safe, highly immunogenic and confer long-lasting… 
Effectiveness of hepatitis A vaccination as post-exposure prophylaxis
TLDR
The elevated effectiveness of HAV vaccination for PEP in HA outbreaks, similar to that of IG, and the long-term protection of active immunization, supports the preferential use of vaccination to avoid secondary cases.
Clinical experience with the inactivated hepatitis A vaccine, Avaxim 80U Pediatric
TLDR
The safety and immunogenicity data presented in this review suggest that the pediatric HAV vaccine is a valuable option in the prevention of HAV infection in children in many areas of the world where the disease remains a healthcare issue.
Immune Response to Hepatitis A and E Viruses
TLDR
As the incidence of HAV infection among children and adolescents has declined in many countries owing to improved socioeconomic status, these individuals are at increased risk of disease later in life because of the lower prevalence of immunity.
Hepatitis A Virus among Drug Users and the Role of Vaccination: A Review
TLDR
Immunization after the administration of anti-HAV vaccine has been demonstrated in DUs even if they have responded significantly less than either the general population or carriers of chronic liver disease.
Changes in the epidemiology of hepatitis A outbreaks 13 years after the introduction of a mass vaccination program
TLDR
The aim of this study was to investigate the evolution of hepatitis A outbreaks in Catalonia and estimate the preventable fraction of cases associated with outbreaks as a measure of the impact of the vaccination program.
...
...

References

SHOWING 1-10 OF 104 REFERENCES
Hepatitis A and B vaccination and public health
TLDR
Hepatitis A vaccine strategy for immunizing toddlers is shifting to those countries with intermediate endemicity where increasing morbidity in adults is being observed, and national policies need to consider hepatitis A vaccination in the context of other public health priorities.
Prevention of hepatitis A by Havrix™: a review
TLDR
A recent consensus concluded that hepatitis A vaccines induce lifelong protection, and thus booster vaccinations against hepatitis A are unnecessary in fully immunized, healthy people, and possible future strategies identified.
Prevention of hepatitis A by Havrix™: a review
TLDR
A recent consensus concluded that hepatitis A vaccines induce lifelong protection, and thus booster vaccinations against hepatitis A are unnecessary in fully immunized, healthy people, and possible future strategies identified.
A review of the long-term protection after hepatitis A and B vaccination.
TLDR
All available data on monovalent and combined hepatitis A and hepatitis B vaccines indicates that there is no support for a hepatitis A or hepatitis B booster when a complete primary vaccination course is offered to immunocompetent individuals.
The underestimated risk of hepatitis A and hepatitis B: benefits of an accelerated vaccination schedule.
  • J. Keystone, J. Hershey
  • Medicine, Biology
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
  • 2008
Safety and immunogenicity of inactivated hepatitis A vaccine in patients with chronic liver disease
TLDR
An inactivated hepatitis A vaccine was safe in patients with chronic liver disease while the immune response was inferior to that observed in healthy subjects reported in a previous study.
Hepatitis A in the era of vaccination.
TLDR
Hepatitis A vaccination will probably remain a low priority for some time in the poorest countries, but shifts in the epidemiologic patterns of disease associated with declining hepatitis A virus transmission are occurring in many regions of the world.
Persistent efficacy of live attenuated hepatitis A vaccine (H2-strain) after a mass vaccination program.
TLDR
Live attenuated hepatitis A vaccine has an obvious long-term effectiveness in prevention and control of HA epidemics through mass vaccination.
Immunogenicity of booster vaccination with a virosomal hepatitis A vaccine after primary immunization with an aluminum-adsorbed hepatitis A vaccine.
TLDR
Epaxal can be successfully used to boost immunization following primary vaccination with an aluminum-adsorbed vaccine, and is well tolerated.
Safety and immunogenicity of hepatitis A vaccine in human immunodeficiency virus-infected patients: a double-blind, randomized, placebo-controlled trial.
TLDR
HepA vaccine was well tolerated and had no effect on the course of HIV infection or plasma HIV RNA load.
...
...